A Double-blind Study Evaluating the Efficacy, Safety, and Tolerability of Zorevunersen in Patients With Dravet Syndrome

Study sponsor: Stoke Therapeutics, Inc · STOK

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.